Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Neutrophil-to-lymphocyte ratio may predict DLBCL prognosis
Key clinical point: The neutrophil-to-lymphocyte ration (NLR) may be useful as a prognostic indicator for DLBCL patients receiving treatment.
Major finding: NLR ≥ 4 was an adverse prognostic factor in DLBCL patients treated with chemoimmunotherapy.
Study details: A learning cohort of 274 patients and a validation cohort of 323 patients were used with ROC analysis.
Disclosures: The authors received funding from a variety of pharmaceutical companies.
Citation:
Beltran BE et al. Clinical Lymphoma Myeloma and Leukemia. 2020; doi.org/10.1016/j.clml.2020.04.016.